Status:
COMPLETED
The Effect of HIV Tat Protein on HCV Replication in an In-vitro Model System
Lead Sponsor:
George Washington University
Conditions:
Human Immunodeficiency Virus (HIV)
Hepatitis C, Chronic
Eligibility:
All Genders
18+ years
Brief Summary
Investigators in the Division of Infectious Diseases and the Departments of Biochemistry and Molecular Biology of The George Washington University Medical Center are carrying out a research study to d...
Detailed Description
Samples will be collected from 4 groups of patients with HIV/HCV infection, identified by the virologic control of either HIV, HCV, or both. Sera will be used in an in-vitro hepatocyte model of hepati...
Eligibility Criteria
Inclusion
- Meets one of the following criteria:
- detectable HIV RNA and detectable HCV RNA
- undetectable HIV RNA (treated) and detectable HCV RNA
- undetectable HIV RNA (treated) and undetectable HCV RNA
- undetectable HCV RNA (mono-infected)
- detectable HCV RNA (mono-infected)
- detectable HIV RNA (mono-infected)
- Participants will be men and women, ages 18 and older, and who are patients being seen in the clinics of the Medical Faculty Associates, and meet the above criteria.
Exclusion
- None
Key Trial Info
Start Date :
July 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2015
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT01206933
Start Date
July 1 2010
End Date
June 1 2015
Last Update
February 10 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
George Washington University Medical Faculty Associates
Washington D.C., District of Columbia, United States, 20037